Primary tumor

Navigating Lung Cancer: 5 Essential Facts Families Should Know About Lung Nodules and Staging

Retrieved on: 
Wednesday, March 27, 2024
Diagnosis, Lung cancer, Metastasis, X-ray, Patient, Research, Cancer, Hope, Lymph, American Lung Association, Prognosis, Physician, Family, Primary tumor, Medical imaging

CHICAGO, March 27, 2024 /PRNewswire/ -- About every two and a half minutes, someone in the U.S. is diagnosed with lung cancer. The diagnosis process usually starts with a suspected "nodule." The process of "suspected nodule" to treatment (or other next steps) can be confusing to a person impacted and their family. To help empower people who are newly diagnosed with lung cancer with critical knowledge about lung nodules, staging and treatment, the American Lung Association and Olympus partnered to launch a new educational campaign.

Key Points: 
  • To help empower people who are newly diagnosed with lung cancer with critical knowledge about lung nodules, staging and treatment, the American Lung Association and Olympus partnered to launch a new educational campaign .
  • While it may seem like a simple step in the diagnostic process, staging lung cancer can be complicated.
  • Here are five things that people should know about lung cancer staging:
    There are 3 main scenarios in which lung nodules are found: Lung nodules show up on imaging tests like X-rays and CT scans.
  • The Lung Association has new resources about staging and lung nodules: Through this campaign, resources are available to provide more information about lung nodules and staging at Lung.org/lung-nodules .

Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia’s TGA

Retrieved on: 
Saturday, December 2, 2023
Orbis, Marketing, Clutch (eggs), NPC, JAMA, Nasopharyngeal carcinoma, Risk, Ministry, OCE, ASCO, Shanda, Radiation, HSA, FDA, Dor, New chemical entity, European, Progression-free survival, Society, Cisplatin, NCE, MHRA, Cancer, Head, Death, American Medical Association, Health Canada, HC, World Health Organization, Primary tumor, Patient, Therapeutic Goods Administration, Safety, PFS, Journal, TGA, Pharmaceutical industry

Additionally, the TGA has also granted an orphan drug designation to toripalimab for the treatment of NPC.

Key Points: 
  • Additionally, the TGA has also granted an orphan drug designation to toripalimab for the treatment of NPC.
  • At present, seven other regulatory agencies have joined Project Orbis, including the TGA, Singapore Health Sciences Authority (HSA), Health Canada (HC), MHRA, etc.
  • Toripalimab for the treatment of NPC meets these application requirements and is the first domestic oncology drug to be included in Project Orbis.
  • Junshi Biosciences will explore the possibility of fast marketing in these countries and regions where the pathway is applicable.

Guthrie Ophthalmologist Named Catholic Doctor of the Year

Retrieved on: 
Friday, November 17, 2023
Difference, African, Glioblastoma, Baylor University, Catholic Church, Patient, Baylor College of Medicine, Well, Friends, University, Glasses, Diagnosis, Primary tumor, Family, Health professional, Sport, Brain, Maryknoll Society, Nursing, Medical device

In 1988, she went on her first medical mission trip to a Catholic Mission Hospital in Abak, Nigeria.

Key Points: 
  • In 1988, she went on her first medical mission trip to a Catholic Mission Hospital in Abak, Nigeria.
  • In 2006, Dr. Schanzer and her husband, at the invitation of local Archbishop Joseph Ganda, established Southern Eye Clinic in Serabu, Sierra Leone.
  • Today, Southern Eye Clinic of Serabu is open year-round, providing diagnostic examinations, medicines, eyeglasses, and modern eye surgery free of charge to all patients.
  • Dr. Schanzer and her husband are grateful for their deep faith and the strong worldwide support of family and friends.

Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

Retrieved on: 
Friday, October 27, 2023
HKEX, FDA, Junshi, SSE, PD-L1, Glomus tumor, Skull, Survival, Harvard Medical School, Primary tumor, Incidence, Aes, Food, Progression-free survival, DCR, Sun, Cisplatin, PFS, Conference, PD-1, CHRS, CCR8, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research, HIV disease progression rates, NPC, Assistant professor, Immune system, Neoplasm, Risk, Pharynx, Radiation, ORR, Platinum, Tumor microenvironment, Cancer, Ira Pastan, Patient, OS, Death, Toxicity, Nose, Palladium, Pharmaceutical industry

REDWOOD CITY, Calif. and SHANGHAI, China, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, NASDAQ: CHRS), and  Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences, HKEX: 1877; SSE: 688180) today announced that the U.S. Food and Drug Administration (FDA) approved LOQTORZI™ (toripalimab-tpzi) in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced NPC, and as monotherapy for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. The approval was based on results of the JUPITER-02 Phase 3 study and the POLARIS-02 Phase 2 study and is irrespective of a patient’s PD-L1 status. LOQTORZI is a next-generation, programmed death receptor-1 (PD-1) monoclonal antibody that blocks PD-1 ligands PD-L1 and PD-L2 with high potency at a unique site on the PD-1 receptor, enabling the immune system to activate and kill the tumor.

Key Points: 
  • The approval was based on results of the JUPITER-02 Phase 3 study and the POLARIS-02 Phase 2 study and is irrespective of a patient’s PD-L1 status.
  • LOQTORZI also demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS), with treatment resulting in a 37% reduction in the risk of death versus chemotherapy alone.
  • “Following etesevimab, toripalimab has become Junshi Biosciences’ second product to receive FDA approval for commercialization—an achievement that will further enhance the company’s international presence.
  • Currently, the establishment of toripalimab’s global commercialization network is in progress, and the network aims to span over 50 countries.

TransCode Therapeutics Reports Successful Treatment of Preclinical Melanoma Tumors with its Immunotherapy Candidate, TTX-RIGA

Retrieved on: 
Monday, October 16, 2023
Neoplasm, Primary tumor, Transcoding, Doctor of Philosophy, Tumor microenvironment, GBM, RNA, Glioblastoma, PRR, Immunity, Therapy, Animal, Toxicity, RNA interference, Recurrence, Cancer, Melanoma, Immunotherapy, CRISPR, Growth, Immune system, TTX, Gene editing, Metastasis, Messenger, Vaccine

BOSTON, Oct. 16, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported successful treatment of preclinical melanoma tumors using its immunotherapy candidate, TTX-RIGA.

Key Points: 
  • BOSTON, Oct. 16, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported successful treatment of preclinical melanoma tumors using its immunotherapy candidate, TTX-RIGA.
  • TTX-RIGA is designed to work by binding to an intracellular receptor called RIG-I (retinoic acid-inducible gene I).
  • TransCode believes this could result in targeted activation of innate immunity in the tumor microenvironment.
  • TransCode believes that understanding how to recruit PRRs, such as RIG-I, in a tumor-selective manner is critical for clinical applications.

First U.S. Patients Undergo Innovative Brain Cancer Treatment in New Clinical Trial at HCA Healthcare’s Johnston-Willis Hospital

Retrieved on: 
Thursday, October 12, 2023
Other Health, Research, General Health, Oncology, Hospitals, Clinical Trials, Science, Surgery, Biotechnology, Neurology, Other Science, Health, Primary tumor, Lung cancer, Essential tremor, Hope, Breast cancer, Brain, Neuroscience, HCA, Hospital, FDA, Joint, Melanoma, Immunotherapy, Clinical trial, Lung, Traffic barrier, HCA Healthcare, Patient, BBB, Medical imaging, Insightec

HCA Healthcare’s Johnston-Willis Hospital in Richmond, Virginia, is the first hospital in the United States to provide treatment in a new clinical trial for patients with brain metastases from lung cancer.

Key Points: 
  • HCA Healthcare’s Johnston-Willis Hospital in Richmond, Virginia, is the first hospital in the United States to provide treatment in a new clinical trial for patients with brain metastases from lung cancer.
  • Johnston-Willis Hospital is hosting the trial and has already enrolled the first two U.S. patients who are currently undergoing a total of six treatment cycles each.
  • The patients have metastatic brain cancer, which originated from cancer cells spreading to the brain from the primary tumor in their lungs.
  • By opening the BBB, non-small cell lung cancer medications may reach and target the critical lesions in the brain.

 Akamis Bio Highlights Data Showing Potential of its Adenovirus Vector Technology in Combination with Radiation to Treat Advanced Rectal Cancer

Retrieved on: 
Tuesday, October 3, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, ENAD Ayiou Dometiou FC, Radiation, University, Therapy, Function, Bio, Cancer Research UK, University college, Research fellow, Antibody, Radiation therapy, Cancer Science, University of Glasgow, MRI, Date, Primary tumor, Transgene, Patient, Monochorionic twins, Master of Science, School, Chemokine, Cytokine, Society, Vaccine, Medical imaging, Safety, Chemoradiotherapy

In the two dose schedules with administration pre-CRT and post-CRT, mrTRG of 1 or 2 was observed in 5 out of 10 (50%) of the treated patients.

Key Points: 
  • In the two dose schedules with administration pre-CRT and post-CRT, mrTRG of 1 or 2 was observed in 5 out of 10 (50%) of the treated patients.
  • Further, hexon staining of patient samples suggested EnAd localization in both the primary tumor and in metastatic sites.
  • “These data are compelling given the higher-than-expected pCR/cCR rate, and the low adverse event rate highlights the ability to deliver the oncolytic virus concurrently with chemoradiation.
  • ET
    Presenter: Dr Séan M. O’Cathail, MSc DPhil MRCPI FRCP FRCR, Senior Research Fellow, School of Cancer Sciences, University of Glasgow

Oxford BioTherapeutics Initiates Phase Ib Clinical Trial for OBT076 in Patients with Advanced Solid Tumors by Dosing First Patient in Combination with CPI Balstilimab in Europe

Retrieved on: 
Wednesday, July 5, 2023
Partnership, AACR, PD, Therapy, CPI, Neoplasm, HER2, Infection, American Society of Clinical Oncology, Pharmacokinetics, American Association for Cancer Research, OBT, CD205, NSCLC, Part, Doctor of Philosophy, Lung, ASCO, Primary tumor, Patient, Data, Phases of clinical research, Immune system, Cancer, ADC, Ovarian cancer, Pembrolizumab, Society, Safety, Pharmaceutical industry, Medical imaging, Vaccine, Agenus

OBT initiates clinical combination study for both CPI-naïve and resistant patients with advanced solid tumors by dosing first patient with OBT076 in combination with checkpoint inhibitor (CPI) balstilimab.

Key Points: 
  • OBT initiates clinical combination study for both CPI-naïve and resistant patients with advanced solid tumors by dosing first patient with OBT076 in combination with checkpoint inhibitor (CPI) balstilimab.
  • This extension of OBT’s US Phase I Clinical Trial for OBT076 will evaluate the clinical efficacy of OBT076 in combination with balstilimab in patients with solid tumors including lung, gastric and ovarian cancer.
  • This extension is designed to build on preliminary data supporting OBT076’s ability to deliver immune priming in chemo-refractory, advanced cancer patients.
  • OBT has also expanded its Phase 1b clinical trial investigating the safety, tolerability and pharmacokinetic profile of OBT076 as a monotherapy in Europe.

RadioMedix and Orano Med Complete Patient Enrolment in Phase II Trial of Targeted Alpha-Emitter AlphaMedix in Neuroendocrine Cancers

Retrieved on: 
Tuesday, May 16, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, NETS, Progression-free survival, TAT, Somatostatin, RECIST, Toxicity, NET, PFS, ORR, Primary tumor, MD, Patient, Phase, FDA, PRRT, Safety, Medical imaging, Pharmaceutical industry

RadioMedix and Orano Med, two clinical stage radiopharmaceutical companies, today announced that the last patient has been dosed in the Phase II trial of the targeted alpha emitter therapy, 212Pb-DOTAMTATE (AlphaMedix™).

Key Points: 
  • RadioMedix and Orano Med, two clinical stage radiopharmaceutical companies, today announced that the last patient has been dosed in the Phase II trial of the targeted alpha emitter therapy, 212Pb-DOTAMTATE (AlphaMedix™).
  • “Previous studies have shown targeted alpha therapy (TAT) with AlphaMedix™ is well-tolerated.
  • Julien Dodet, President, and Chief Executive Officer of Orano Med, noted: “Completing this Phase II trial enrolment on schedule is a great achievement everyone involved and confirms the strong interest of the medical community for targeted alphatherapies with lead-212.
  • This reinforces Orano Med’s commitment to make innovative lead-212-based therapies available to the medical community and patients worldwide.”

NanOlogy Granted a US Patent for Its Investigational Drugs in Combination with Immune Checkpoint Inhibitors in the Treatment of Cancer

Retrieved on: 
Tuesday, March 7, 2023
Managed Care, Research, Radiology, Pharmaceutical, Oncology, Infectious Diseases, Genetics, Clinical Trials, Science, Biotechnology, FDA, Health, Other Science, MD, Pancreas, Treatment, Toxic epidermal necrolysis, Toxicity, Patent, Prostate, ICIS, LSAM, Lung, Patient, Neoplasm, Immune system, Primary tumor, Pharmaceutical industry, Medical imaging, Cancer

The patent ( 11,583,499 ) is valid in the US until November 25, 2038, and has corresponding filings globally.

Key Points: 
  • The patent ( 11,583,499 ) is valid in the US until November 25, 2038, and has corresponding filings globally.
  • ICIs are often used in combination with other systemic cancer therapies particularly in the treatment of solid tumors to prime the immune system to increase response.
  • “The Cancer Research Institute estimates more than 5000 clinical trials are underway worldwide with immune checkpoint inhibitors; many are combination trials with other systemic cancer agents in solid tumors.” said Gere DiZerega, MD, NanOlogy Chief Medical Officer.
  • “The goal is to identify which combinations can increase the immune response thereby increasing the overall solid tumor response to treatment.